NICE publishes latest drug decisions

The National Institute of Clinical Excellence (NICE) has issued its latest decisions on the use of drugs on the NHS in England and Wales.

The agency has accepted denosumab for restricted use in the prevention of osteoporotic fragility fractures in postmenopausal women. Liraglutide, at a daily dose of 1.2mg, is accepted for restricted use in dual and triple therapy of patients with type 2 diabetes.

NICE was unable to recommend bendamustine for the treatment of indolent rituximab-resistant non-Hodgkin’s lymphoma because no supporting evidence was submitted. For the same reason, temsirolimus could not be recommended for the treatment of relapsed or refractory mantle cell lymphoma.

The agency also rejected ofatumumab for the treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab; omalizumab for severe persistent allergic asthma in children aged 6 to 11 years; and eltrombopag for chronic immune (idiopathic) thrombocytopenic purpura.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases